Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. - Wikidata - awgldk - TriplyDB

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

http://www.wikidata.org/entity/Q47254055

about

Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments Medical treatment of early stage and rare histological variants of epithelial ovarian cancer HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies Better therapeutic trials in ovarian cancer.Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment Pathobiology of ovarian carcinomas New perspectives on targeted therapy in ovarian cancer Prioritizing therapeutic targets using patient-derived xenograft models Type-specific cell line models for type-specific ovarian cancer research Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.Trismus and diffuse polymyalgia: an unusual presentation of recurrent metastatic ovarian cancer.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.Optimizing Ventana chromogenic dual in-situ hybridization for mucinous epithelial ovarian cancer.Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.A qualitative study comparing the assay performance characteristics between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 scoring methods in mucinous epithelial ovarian cancer.ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer Genetic and molecular changes in ovarian cancer.New developments in the treatment of ovarian cancer--future perspectives.Clinical implications of using molecular diagnostics for ovarian cancers.Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.Implications of intratumour heterogeneity for treatment stratification.Targeted therapies and clinical trials in ovarian cancer.Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.Current and emerging treatment options in the management of advanced ovarian cancer.Mucinous epithelial ovarian carcinoma.Identification of novel candidate biomarkers of epithelial ovarian cancer by profiling the secretomes of three-dimensional genetic models of ovarian carcinogenesis.Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study.

P2860

Q26740622-4A0E6331-7623-426F-BAAD-93C35028CE69 Q26750649-A46172D6-367B-46AD-9946-1970F2AD60A3 Q26777702-1492597C-9BE8-4F78-9237-3E643573E237 Q26822730-C306F9CE-1BCB-4EAA-8CC4-F045BD3B568D Q27691432-625AE86C-6661-48F7-95F8-3A0725160611 Q28066904-68B63563-046D-4939-A6A9-566BC4E1FB13 Q28080478-1BE91545-E26C-4584-8559-86C0351E2244 Q28082524-151FAA93-22CF-4A1C-B6D8-D0BB2B13C4E1 Q28083993-23CC81F3-7139-457B-9D7F-96F2F672C8B3 Q28536689-CA191BE8-7C4D-41F2-957C-4E00413E50EF Q30276986-7D1FC0A8-5A62-49BA-99A9-703DBCE353FB Q33629082-D28A5AA9-D978-469B-BC4F-EB456B938A4A Q33735170-3264046F-F75C-4D02-A55F-8A8F116F64C6 Q34029209-02653A9D-2BAB-4DD7-8D3D-CF9FDB4CE0F0 Q34528553-9A0EA577-6939-46B5-A103-C131CDB3CB2E Q34688984-A8064349-4735-4339-B145-47A263646845 Q35076986-BF3B29F4-D052-406A-9162-2BC46175728B Q35634450-7B0B56A1-BE5C-4285-959A-AE49ADA2B83D Q35841024-4A577589-62AF-4C12-938A-E1A2BA30577A Q35926362-F7B70A43-8C0D-425D-BF33-455142F5E09B Q36152629-F94CD75E-BE98-40FB-85B2-3D2E2F7F4610 Q36155553-93FE68FB-1627-4975-9176-AE4546C50F34 Q36157106-108D882C-7A7B-42A0-9A41-2A7B2E64FDCC Q36855239-AA15426C-AB83-44E5-B00F-F255C0C46FC0 Q37094076-3FCDA43F-96B9-4C86-8620-22390148FB2B Q37332487-B4D20E9A-C7BD-4522-A6FC-F90CF802406C Q37332490-DD8C087F-4F57-4110-922C-E9E89B59E3F1 Q37632101-43CFD9FC-22BB-48FA-B64C-3502FCE2BCEF Q37696086-94288E53-EB43-4C0E-A659-8968FFCAA0BC Q38067436-F6CDCCD6-092B-44A6-8178-1FDDD9149CCE Q38151633-15B491C7-A776-45AC-9C74-57AB4078ADDC Q38165164-1A95B5E4-D5BC-423D-8AAE-293D736AAE54 Q38170493-8ED0B6C6-C926-46BF-94FD-AA6C315AE9E1 Q38205584-D5991412-5D34-4155-8D3A-B67B8E76357A Q38374680-A0C74A69-C7F8-45FF-8601-82504A602552 Q38378337-D7010518-E299-4BFF-BF43-C052288AECFA Q38751236-A7AB0CD6-DAFD-466A-B10B-FD5013605265 Q38824322-2B927C01-0912-492D-B0F4-B677442260D7 Q38958066-D8740FEF-E669-4F51-889D-9C41BD1D8B53 Q39176734-BD2FBE88-F307-470E-AC6B-B25F7B16A900

P2860

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

http://www.wikidata.org/entity/Q47254055

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Molecular characterization of ...... argeting in 19% of carcinomas.

@en

Molecular characterization of ...... argeting in 19% of carcinomas.

@nl

type

label

Molecular characterization of ...... argeting in 19% of carcinomas.

@en

Molecular characterization of ...... argeting in 19% of carcinomas.

@nl

prefLabel

Molecular characterization of ...... argeting in 19% of carcinomas.

@en

Molecular characterization of ...... argeting in 19% of carcinomas.

@nl

P1433

Q47254055-F8D37313-38A4-433E-A764-AD002790B1AC

P1476

Q47254055-FAA0A6B9-1A9E-410C-A76B-09F84FD79E6B

P2093

Q47254055-01CD1AF5-BF0F-445F-8AE6-A8ACFC530FC0

Q47254055-2D262CCC-53CD-4498-9524-5CB99F21F53A

Q47254055-36E6C43C-916C-418F-851F-BF0676AE79CD

Q47254055-5F392F76-C68E-4203-962F-48FD40EB3B4C

Q47254055-5FA22A75-AE0D-4D9C-ABC5-580B1299B6D0

Q47254055-6B51B533-A8B5-4227-943A-D2830D4C3F62

Q47254055-6BFD2614-F0FB-4742-BC5A-5A81EA4B72E2

Q47254055-70602608-D0EA-4852-A839-9EB25F783348

Q47254055-747D585E-0701-49A9-8B7C-4636AF7FC6FD

Q47254055-783494AC-F859-4739-9DA6-64C6043A6E85

P2860

Q47254055-0DC444FB-0DE4-488A-B279-474C312C155A

Q47254055-0F7ECD80-DBA8-425E-B984-C40C71C280D3

Q47254055-1034B2AA-71B6-41E7-9B8B-6298AAD3439C

Q47254055-129CFD54-ACBD-42CF-B96B-64EA56CB15BB

Q47254055-2CD3744D-CAA7-4C4D-9922-346C3A82FC33

Q47254055-33AABF92-8BAE-45A4-964D-11EDD40B3D76

Q47254055-38AE4B7F-2828-4EA1-9A87-7D7E45472A30

Q47254055-4A05C089-3386-4C06-858A-D22926949A53

Q47254055-50F04241-E759-4415-91A6-21A32D2B1E39

Q47254055-57A13866-B1D8-4D7D-B2F2-ECF843368EEE

P304

Q47254055-885668DC-FCC8-4691-9BC3-A3815F15A5EB

P31

Q47254055-57EDF379-F0AD-4729-B053-3583223EC799

P356

Q47254055-F183548E-D7C7-4850-8B14-EFEA85B3F62F

P433

Q47254055-3709E3CE-0C04-4F6D-942F-472808AD5935

P478

Q47254055-F4B55BEC-C594-48C8-BDC7-3CA3C84FFD05

P50

Q47254055-5A7D11BF-FA62-40AA-A979-BB493F13F108

Q47254055-9BB74181-43CB-4717-89E1-8A228639075A

Q47254055-CEEC51C6-9FE8-4BB9-B3DD-4394B11CDFE1

P577

Q47254055-F684D365-7CEE-4230-9337-005457017979

P698

Q47254055-9FD98F71-BC36-4298-991E-D5A5B22913DA

P356

P1433

The Journal of Pathology

P1476

Molecular characterization of ...... targeting in 19% of carcinomas

@en

P2093

Anna V Tinker

http://www.w3.org/2001/XMLSchema#string

Attila Teoman

http://www.w3.org/2001/XMLSchema#string

Boris J Winterhoff

http://www.w3.org/2001/XMLSchema#string

C Blake Gilks

http://www.w3.org/2001/XMLSchema#string

David G Huntsman

http://www.w3.org/2001/XMLSchema#string

Ghassan Allo

http://www.w3.org/2001/XMLSchema#string

Helen Steed

http://www.w3.org/2001/XMLSchema#string

Henry Porter

http://www.w3.org/2001/XMLSchema#string

Jamie Bakkum-Gamez

http://www.w3.org/2001/XMLSchema#string

Janine Senz

http://www.w3.org/2001/XMLSchema#string

P2860

Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data.

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

Targeting SRC in mucinous ovarian carcinoma.

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

Calculator for ovarian carcinoma subtype prediction.

Strategy for randomised clinical trials in rare cancers.

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

P304

111-120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PATH.4088

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

229

http://www.w3.org/2001/XMLSchema#string

P50

Michael S Anglesio

Blaise A Clarke

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22899400

http://www.w3.org/2001/XMLSchema#string